Tesamorelin Research Guide
2mg · Research compound — not for human consumption
Research Overview
Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone (GHRH) developed by Theratechnologies and studied extensively in the research literature, including clinical investigation of visceral adipose tissue in HIV-associated lipodystrophy. As supplied here, it is intended for laboratory research only and is not intended for human consumption.
Structural & Class Overview
A 44-amino-acid GHRH analog featuring an N-terminal trans-3-hexenoic acid modification that research describes as increasing resistance to enzymatic degradation relative to endogenous GHRH. It is classified as a GHRH-receptor agonist signaling through the cAMP/PKA pathway in pituitary somatotrophs.
General Research Interest
Research interest includes GHRH-receptor activation and stability of the modified peptide; growth-hormone-driven lipolysis in visceral adipose-tissue models; hepatic fat and metabolic-parameter studies; preservation of pulsatile growth-hormone release patterns; and growth-hormone/IGF-I axis signaling.
Storage Considerations
Store the lyophilized research peptide cool and dark, and protect from light, heat, and moisture. Reconstituted material is generally handled under refrigeration for laboratory use. For research handling only; not for human use.
Testing & Quality Considerations
Quality considerations for research material include HPLC purity assessment, mass-spectrometry identity confirmation, and verification against a batch Certificate of Analysis (COA).
References
- Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy (PMC)
- Tesamorelin — an overview (ScienceDirect Topics)
References are provided for scientific context. Linked sources are independent and not affiliated with iNGEN MD.
